Merck drug shows strong survival benefit in early melanoma study
This article was originally published in Scrip
More than 80% of patients with advanced melanoma lived after a year of treatment with a Merck & Co experimental medicine that triggers the immune system to fight cancer, early data show.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.